Results 171 to 180 of about 146,874 (392)

Artificial Intelligence and the Evolving Landscape of Immunopeptidomics

PROTEOMICS – Clinical Applications, EarlyView.
ABSTRACT Background Immunopeptidomics is the large‐scale study of peptides presented by major histocompatibility complex (MHC) molecules and plays a central role in neoantigen discovery and cancer immunotherapy. However, the complexity of mass spectrometry data, the diversity of peptide sources, and variability in immune responses present major ...
Thanh Hoa Vo, Edel McNeela, Orla O'Donovan, Sweta Rani, Jai Prakash Mehta   +4 more
wiley   +1 more source

HER2 Is Frequently Over‐expressed in Ovarian Clear Cell Adenocarcinoma: Possible Novel Treatment Modality Using Recombinant Monoclonal Antibody against HER2, Trastuzumab [PDF]

, 2002
Masaki Fujimura, Noriyuki Katsumata, Hiroshi Tsuda, Naoko Uchi, Satomi Miyazaki, Takao Hidaka, Masatoshi Sakai, Shigeru Saito   +7 more
openalex   +1 more source

Synthesis and Feasibility Evaluation of a new Trastuzumab Conjugate Integrated with Paclitaxel and 89Zr for Theranostic Application Against HER2‐Expressing Breast Cancers

ChemistryOpen, 2019
The preparation and in vitro evaluation of a theranostic conjugate composed of trastuzumab, paclitaxel (PTX), and deferoxamine (DFO)‐chelated 89Zr have been reported.
Dr. Joo Hee Jang, Sang Jin Han, Dr. Jung Young Kim, Dr. Kwang Il Kim, Dr. Kyo Chul Lee, Dr. Chi Soo Kang   +5 more
doaj   +1 more source

Eficacia de la combinación de Vinorelbine- Trastuzumab en carcinoma de mama metastásico con sobreexpresión de HER2, previamente tratado con Trastuzumab [PDF]

, 2013
L'addició de Trastuzumab a quimioteràpia basada en taxans millora la supervivència de les pacients amb carcinoma de mama metastàtic i sobreexpressió de HER2.
Cortés, Javier, Rodríguez Freixinós, Víctor, Suriñach Caralt, Josep Mª, Universitat Autònoma de Barcelona. Departament de Medicina, Universitat Autònoma de Barcelona. Facultat de Medicina   +4 more
core  

Postmarketing Assessment of Antibody–Drug Conjugates: Proof‐of‐Concept Using Model‐Based Meta‐Analysis and a Clinical Utility Index Approach

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Antibody–drug conjugates (ADCs) are a promising class of targeted cancer therapies. However, they need careful dose optimization to maximize effectiveness and minimize side effects. Sometimes, safety issues may only become apparent after approval, so ongoing evaluation is important.
Innocent Gerald Asiimwe, Nour Chtiba, Samer Mouksassi, Goonaseelan (Colin) Pillai, Raimund M. Peter, Eunice Yuen, Venkatesh Pilla Reddy   +6 more
wiley   +1 more source

Mitigating Trastuzumab‐Doxorubicin Cardiotoxicity With Multiscale Quantitative Systems Toxicology and PBPK‐Toxicodynamic Predictive Modeling Framework

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Doxorubicin (DOX) and trastuzumab (TmAb) are widely used to treat HER2‐positive breast cancer (BC), as monotherapies and in combination (DOX + TmAb). While highly effective, their combined use significantly increases the risk of irreversible cardiotoxicity, posing a major clinical concern.
Sijia Yu, Hardik Mody, Tanaya R. Vaidya, Leonid Kagan, Sihem Ait‐Oudhia   +4 more
wiley   +1 more source

Population Pharmacokinetic Analysis of Datopotamab Deruxtecan (Dato‐DXd), a TROP2‐Directed Antibody‐Drug Conjugate, in Patients With Advanced Solid Tumors

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Datopotamab deruxtecan (Dato‐DXd) is a trophoblast cell surface antigen 2 (TROP2)‐directed antibody‐drug conjugate (ADC) developed for the treatment of advanced or metastatic solid tumors. Dato‐DXd demonstrated promising antitumor activity and a manageable safety profile in the first‐in‐human Phase 1 study TROPION‐PanTumor01.
Ying Hong, Sophie Peigné, Υuzhuo Pan, Sofia Friberg Hietala, Anna McLaughlin, Naoyuki Tajima, Deise Uema, Hong Zebger‐Gong, Zoey Tang, Diansong Zhou, Malaz Abutarif, Τushar Garimella   +11 more
wiley   +1 more source

Bioengineered Extracellular Vesicles in Emerging Cancer Vaccine Platforms

Small Science, EarlyView.
This review highlights recent advances in engineering extracellular vesicles (EVs) as next‐generation cancer vaccines. It outlines their biological roles and antigen‐presenting capacity, explores key strategies for antigen loading and delivery optimization, and summarizes preclinical and clinical applications using EVs from diverse immune and tumor ...
Wonkyung Ahn, Yeram Lee, Gi‐Hoon Nam, Jae Bem You, Eun Jung Lee   +4 more
wiley   +1 more source

Effects of trastuzumab on epidermal growth factor receptor-dependent and -independent human colon cancer cells [PDF]

, 2003
Scott K. Kuwada, Courtney L. Scaife, Jinqiu Kuang, Xiufen Li, Robert F. Wong, Scott R. Florell, Robert J. Coffey, Phillip D. Gray   +7 more
openalex   +1 more source

Exome‐wide molecular insights from blood and urine liquid biopsies in genitourinary cancers

UroPrecision, EarlyView.
Abstract Background Liquid biopsy has emerged as a non‐invasive method for real‐time cancer monitoring especially in genitourinary (GU) oncology. Most current studies utilize a panel‐based molecular profiling ranging from 50–600 genes; however, a comprehensive exome‐wide profiling of real‐world patient samples has been lacking. Methods Over 2000 liquid
Eric Jia, Tiantian Zheng, Yong Huang, Pan Du   +3 more
wiley   +1 more source